ABBV-011, A Novel, Calicheamicin-Based Antibody–Drug Conjugate, Targets SEZ6 to Eradicate Small Cell Lung Cancer Tumors

Overview of attention for article published in Molecular Cancer Therapeutics, June 2022

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (82nd percentile)
High Attention Score compared to outputs of the same age and source (85th percentile)

So far, Altmetric has seen 6 X posts from 6 X users, with an upper bound of 8,315 followers.

RT @MCT_AACR: #AntibodyDrugConjugate ABBV-011 induces a potent anti-tumor effect resulting in regression in #SmallCellLungCancer PDX models…

#AntibodyDrugConjugate ABBV-011 induces a potent anti-tumor effect resulting in regression in #SmallCellLungCancer PDX models. It is currently tested in a Phase 1 clinical study. https://t.co/HO3YGVS9rv https://t.co/S3Q4bjg5bG

Cáncer Pulmón Microcítico. #BBV_011 (BY #ABBVIE), Un Nuevo #Anticuerpo_Conjugado a Base de #Caliqueamicina, se Dirige a #SEZ6 Para Erradicar los Tumores de Cáncer de Pulmón de Células Pequeñas (SMALL CELL LUNG CANCER). https://t.co/vSJ8v0MD5P, #SCLC #LUNGC

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 2 additional X posts.